A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 31 Jul 2023 Planned initiation date changed from 31 Jul 2023 to 26 Jul 2023.
- 25 Jul 2023 Planned initiation date (estimated date for recruitment of the first subject) changed to 31 Jul 2023.
- 27 Jun 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 29 Jun 2023 to 3 Jul 2023.